Most Anticipated Drug Launches of 2023

Letting new drugs into the market is never easy, so only a few entries get passed the strict FDA regulations annually.  Those that do pass, though, have the potential to enrich the current drug market and make it easier for both physicians and patients to get the most out of treatments.  Regarding the types of […]

What is a CRO in Clinical Trials?

When it comes to coming up with a new drug, treatment, or way of handling any ailment or trauma, testing the waters first is essential for preventing the new drug from having exactly the opposite effect of the initially intended one.  Now, clinical trials often take a long time for well-justified reasons.  Rather than giving […]

Cardiovascular Outcomes Trials Answer Long-Asked Questions – But New Questions Arise

The recent American Diabetes Association’s 75th Scientific Sessions in Boston saw the release of data from the ELIXA cardiovascular outcomes trial (CVOT) for lixisenatide (Sanofi/Zealand Pharma’s Lyxumia), the first such trial completed for the GLP-1 receptor agonist drug class. However, it was the publication of the data from the CVOT for sitagliptin (Merck’s Januvia/Ono’s Glactiv), […]

Vigilant Biosciences Announces Agreement with Eurobio for Exclusive Distribution of the OncAlert™ Oral Cancer Risk Assessment System in France, Algeria, Morocco and Tunisia

Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today that it has entered into a three-year exclusive sales and marketing agreement with Eurobio for the distribution of the OncAlert Oral Cancer Risk Assessment System in France, Algeria, Morocco and Tunisia. The […]

First Biogen Inc, Now Roche Holding Ltd. : Rays Of Hope For An Alzheimer’s Cure

After Biogen’s success in slowing down Alzheimer’s progress in early-stage trials, Roche Holding intends to take its own Alzheimer’s candidate on a trial re-run Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) is considering the initiation of a second trial to test its investigational Alzheimer’s drug that was abandoned in December after a disappointing initial study, Bloomberg reports. […]

Merck Submits U.S. New Drug Application for Grazoprevir/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for grazoprevir/elbasvir (100mg/50mg), an investigational once-daily, single tablet combination therapy for the treatment of adult patients with chronic hepatitis C genotypes (GT) 1, 4 or […]

Virotherapy: Skin Cancer Successfully Treated With Herpes-Based Drug

Virotherapy’ uses modified herpes virus to attack melanoma cells and has potential to overcome cancer even when disease has spread throughout the body. Patients with aggressive skin cancer have been treated successfully using a drug based on the herpes virus, in a trial that could pave the way for a new generation of cancer treatments. […]

Biomedical Research: Diagnosis of Deputies

The law N° 28-13, introduced in June 2014, was finally adopted by the chamber of deputies. The impact of this new legislation on the development of biomedical research was highlighted by the committee of social sectors. Members have declared the gap in the law that has long prevailed in this area and has negatively impacted […]

Algeria: Nearly DZD 180 Billion Devoted to 2015-2019 National Anti-Cancer Plan

Algiers — The overall cost of the 2015-2019 anti-cancer national plan has been estimated at nearly DZD 180 billion, according to a report on the plan presented Sunday at the Council of Ministers by the Minister of Health, Population and Hospital reform. “The total cost of the 2015-2019 national anti-cancer plan has been estimated at […]

Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer in Previously-Treated Patients

Nivolumab is the first PD-1 immune checkpoint inhibitor to receive a positive opinion from the CHMP in advanced non-small cell lung cancer Opinion based on overall survival benefit demonstrated in CheckMate -017 CHMP positive opinion marks the second for nivolumab; positive opinion for advanced melanoma was received in April 2015 PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company […]

Regeneron (REGN), Sanofi (SNY) Announce Sarilumab Met co-Primary Endpoints in Phase 3

Regeneron (NASDAQ:REGN) and Sanofi (NYSE:SNY) announced that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo. The study, called SARIL-RA-TARGET, evaluated the […]

New Drug Combination Could Extend Life of Cystic Fibrosis Patients

An international research team has demonstrated that a combination of two different drugs targeting the most common genetic cause of cystic fibrosis helped to improve lung function and reduce the rate of pulmonary exacerbations. “These results represent a further major advance in finding treatments which correct the basic problem in cystic fibrosis and improve the […]